Drug makers' attempts to find treatments for Alzheimer's disease have produced scant results and a long string of busts. Now a broad effort is under way to learn something from those failures.
A group of major pharmaceutical companies will share pooled data from failed clinical trials in an attempt to figure out what is going wrong in the studies and what can be done to improve drug development.
In the first wave, data from 4,000 patients across 11 failed Alzheimer's-drug clinical trials from Johnson & Johnson, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi-Aventis and Abbott Laboratories will be publicly available as of Friday.
No comments:
Post a Comment